Home » Osiris Therapeutics Gets FDA Clearance to Broaden Expanded Access Program
Osiris Therapeutics Gets FDA Clearance to Broaden Expanded Access Program
Osiris Therapeutics, Inc. revealed U.S. Food and Drug Administration clearance to broaden its expanded access program for Prochymal, now making the investigational stem cell product available to adults with life-threatening Graft vs. Host Disease.
RTTNews
RTTNews
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May